What is the long-term trend for Arbutus Biopharma Corporation's accrued investment income?

Over 3 years (2022 to 2025), Arbutus Biopharma Corporation's accrued investment income has grown at a -20.6% compound annual growth rate (CAGR), from $600K to $300K.

Arbutus Biopharma Corporation ABUS Accrued investment income

Accrued investment income at other companies

SiriusPointSPNT

$41.4M-1.7%

Voya FinancialVOYA

$426M-0.7%

Mercury GeneralMCY

$73.38M+18.6%

Lincoln NationalLNC

$1.17B+3.2%

Trico BancsharesTCBK

$32.66M+0.4%

NMI Holdings Inc.NMIH

$29.73M+25.7%

Other financials

Income statement

See full

Revenue$179.1M+10,055%

Operating income$168.9M+757%

Net income$169.7M+792%

EPS (diluted)$0.87+769%

Balance sheet

See full

Cash & equivalents$23.7M-36.1%

Total debt$631.0K-46.9%

Total equity$260.2M+229%

Total assets$277.2M+137%

Cash flow

See full

Operating cash flow-$8.1M+39.4%

CapEx--100%

Free cash flow-$4.7M+55.0%

Valuation

See full

Market cap$871.14M+32.6%

Enterprise value$848.07M+36.6%

P/E5.4×—

P/S4.6×-98.0×

Profitability

See full

Operating margin81.7%+42.1pp

Net margin84%+43.4pp

FCF margin-281.5%-119pp

Returns & leverage

See full

Return on equity94.7%+65.1pp

Debt / equity0×0.0×

Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:AccruedInvestmentIncomeReceivable.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's accrued investment income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arbutus Biopharma Corporation's accrued investment income?: Arbutus Biopharma Corporation (ABUS) reported accrued investment income of $300K in Q1 2026.
How has Arbutus Biopharma Corporation's accrued investment income changed year-over-year?: Arbutus Biopharma Corporation's accrued investment income increased by 50.0% year-over-year, from $200K to $300K.
What is the long-term trend for Arbutus Biopharma Corporation's accrued investment income?: Over 3 years (2022 to 2025), Arbutus Biopharma Corporation's accrued investment income has grown at a -20.6% compound annual growth rate (CAGR), from $600K to $300K.